ClinicalTrials.gg
CompletedNCT01419041Updated Oct 1, 2012

A Study to Evaluate The Pharmacokinetics Of Crizotinib (PF-02341066) In Subjects With Impaired Renal Function

A Phase 1 interventional study of crizotinib and crizotinib in Renal Impairment, sponsored by Pfizer. Completed at 3 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-10-01.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies in Renal Insufficiency by Pfizer — 2 open to participants now, 3 under way, none of them phase 3. Renal Insufficiency · Pfizer.

Enrollment
27th of 36
16 · median 30
Started
2011
the only one that year
Phase 1
23 of 37
2 open now
Registered
16th of 37
by date

Among the 37 studies in Renal Insufficiency by Pfizer, this one is the 27th largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2011, is one of 23 in phase 1, and was the 16th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

2 of the 37 studies in Renal Insufficiency by Pfizer are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Renal Insufficiency by Pfizer, or all of them as a file.
02

Study summary

The present study is being conducted to evaluate whether or not severe renal impairment has an effect on crizotinib Pharmacokinetics.

03

Conditions studied

  • Renal Impairment

Browse trials for

Keywords

  • renal impairment
  • crizotinib
  • pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Subjects

  • Healthy male and/or female of non subjects between the ages of 18 and 65 years, inclusive ('healthy' is defined as no abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead , and clinical laboratory tests).
  • (BMI) of 18 to 40 kg/m2 inclusive; and a total body weight >50 kg (>110 lbs).

Subjects with Normal Renal Function (Group 1)

  • Normal renal function ( =>90 mL/min) during the screening period.
  • Matched 1-to-1 to subjects in Group 2 with respect to age (+/-5 years), weight (+/-10 kg), gender, and race according to protocol.

Subjects with Severe Renal Impairment (Groups 2)

  • Good general health commensurate with the population with chronic kidney disease.
  • Severe renal impairment (CLcr\<30 mL/min) during the screening period.

Exclusion criteria

Exclusion Criteria:

All Subjects

  • Renal allograft recipients.
  • Any condition possibly affecting drug absorption.
  • 12 lead demonstrating >470 msec at screening.
  • Urinary incontinence without catheterization.
  • A positive urine drug screen.
  • History of regular alcohol consumption.
  • Treatment with an drug within 30 days (or as determined by the local requirement, whichever is longer) or 5 half lives preceding the first dose of study medication.
  • Pregnant or nursing females; females of , including those with tubal ligation.
  • Blood donation of approximately 1 pint (500 mL) within 56 days prior to dosing.

Subjects with Severe Renal Impairment (Groups 2)

  • Subjects with any significant hepatic, cardiac or pulmonary disease (apart from stable ischemic heart disease), or subjects who are clinically nephrotic.
  • Subjects requiring hemodialysis.
  • Subjects with strict fluid restriction (ie, \<1500 mL/24 hours).
  • Significant bleeding diathesis which could preclude multiple venipuncture.
  • Use of food or drugs that are inhibitors and inducers.
  • Herbal supplements and hormone replacement therapy must be discontinued 28 days prior to the first dose of trial medication
  • Concurrent use of drugs that are CYP3A4 substrates with narrow therapeutic indices.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Other
    Arm A

    CLCR: Creatinine clearance

    Drug: crizotinib

  • Other
    Arm B

    CLCR: Creatinine clearance

    Drug: crizotinib

Interventions

  • Single-dose oral 250 mg crizotinib in subjects with normal renal function (CLcr =\>90 mL/min)

  • Single-dose oral 250 mg crizotinib in subjects with severe renal impairment (CLcr \<30 mL/min)

06

What researchers measure

Primary outcomes

  1. Plasma AUCinf (Area under the plasma concentration versus time curve from zero to infinity) for crizotinib

    Time frame: 18 months

  2. Plasma Cmax (Maximum plasma concentration) for crizotinib

    Time frame: 18 months

Secondary outcomes

  1. Plasma AUClast (Area under the plasma concentration versus time curve from zero to the last quantifiable concentration) for crizotinib

    Time frame: 18 months

  2. Tmax (Time to Cmax) for crizotinib

    Time frame: 18 months

  3. t1/2 (terminal half-life) for crizotinib

    Time frame: 18 months

  4. CL/F (Apparent oral clearance) for crizotinib

    Time frame: 18 months

  5. Vz/F (Apparent volume of distribution after oral dose) for crizotinib

    Time frame: 18 months

  6. fu (fraction of unbound drug in plasma) for crizotinib

    Time frame: 18 months

  7. AUCinf,u (unbound AUCinf) for crizotinib

    Time frame: 18 months

  8. AUClast,u (unbound AUClast) for crizotinib

    Time frame: 18 months

  9. Cmax,u (unbound Cmax) for crizotinib

    Time frame: 18 months

  10. CL/Fu (unbound apparent oral clearance) for crizotinib

    Time frame: 18 months

  11. CLR (Renal clearance) for crizotinib

    Time frame: 18 months

  12. Ae (Cumulative amount of drug recovered unchanged in the urine) for crizotinib

    Time frame: 18 months

  13. Ae% (Cumulative amount of drug recovered unchanged in the urine expressed as fraction of administered dose) for crizotinib

    Time frame: 18 months

  14. AUCinf (Area under the plasma concentration versus time curve from zero to infinity) for PF-06260182

    Time frame: 18 months

  15. AUClast (Area under the plasma concentration versus time curve from zero to the last quantifiable concentration) for PF-06260182

    Time frame: 18 months

  16. Cmax (Maximum plasma concentration) for PF-06260182

    Time frame: 18 months

  17. Tmax (Time to Cmax) for PF-06260182

    Time frame: 18 months

  18. t1/2 (terminal half-life) for PF-06260182

    Time frame: 18 months

  19. fu (fraction of unbound drug in plasma) for PF-06260182

    Time frame: 18 months

  20. AUCinf,u (unbound AUCinf) for PF-06260182

    Time frame: 18 months

  21. AUClast,u (unbound AUClast) for PF-06260182

    Time frame: 18 months

  22. Cmax,u (unbound Cmax) for PF-06260182

    Time frame: 18 months

07

Study locations

3 sites
  • Pfizer Investigational Site
    Anaheim, California 92801, United States
  • Pfizer Investigational Site
    DeLand, Florida 32720, United States
  • Pfizer Investigational Site
    Saint Paul, Minnesota 55114, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2011
First posted
Aug 17, 2011
Start
Nov 2011
Primary completionActual
Aug 2012
CompletionActual
Aug 2012
Last update
Oct 1, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01419041
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 17, 2011
Start date
Nov 2011
Primary completion
Aug 2012
Completion
Aug 2012
Last update
Oct 1, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Crizotinib

Start the discussion